• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

咯萘啶(本芴醇)对喀麦隆雅温得恶性疟原虫临床分离株的体外活性

In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon.

作者信息

Basco L K, Bickii J, Ringwald P

机构信息

Institut Français de Recherche Scientifique pour le Développement en Coopération (ORSTOM)- Organisation de Coordination pour la lutte contre les Endémies en Afrique.

出版信息

Antimicrob Agents Chemother. 1998 Sep;42(9):2347-51. doi: 10.1128/AAC.42.9.2347.

DOI:10.1128/AAC.42.9.2347
PMID:9736561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC105831/
Abstract

The in vitro antimalarial activity of the new Chinese synthetic drug, lumefantrine, also known as benflumetol (a fluorene derivative belonging to the aminoalcohol class), was determined by an isotopic microtest against 61 fresh clinical isolates of Plasmodium falciparum and compared with that of other established antimalarial agents. The geometric mean 50% inhibitory concentration of lumefantrine was 11.9 nmol/liter (95% confidence intervals, 10.4 to 13.6 nmol/liter; range, 3.3 to 25.6 nmol/liter). The in vitro activities of lumefantrine against the chloroquine-sensitive and the chloroquine-resistant isolates did not differ (P > 0.05). There was a significant positive correlation of responses between lumefantrine and two other aminoalcohols studied, mefloquine (r = 0.688) and halofantrine (r = 0.677), and between lumefantrine and artesunate (r = 0.420), suggesting a potential for in vitro cross-resistance. Our data suggest high in vitro activity of lumefantrine, comparable to that of mefloquine, and are in agreement with the promising results of preliminary clinical trials.

摘要

新型中国合成药物本芴醇(又称氯氟菲醇,属于氨基醇类的芴衍生物)的体外抗疟活性,通过同位素微量试验针对61株恶性疟原虫新鲜临床分离株进行了测定,并与其他既定抗疟药物的活性进行了比较。本芴醇的几何平均50%抑制浓度为11.9纳摩尔/升(95%置信区间为10.4至13.6纳摩尔/升;范围为3.3至25.6纳摩尔/升)。本芴醇对氯喹敏感和氯喹耐药分离株的体外活性没有差异(P>0.05)。本芴醇与另外两种研究的氨基醇甲氟喹(r=0.688)和卤泛群(r=0.677)之间,以及本芴醇与青蒿琥酯(r=0.420)之间的反应存在显著正相关,表明存在体外交叉耐药的可能性。我们的数据表明本芴醇具有较高的体外活性,与甲氟喹相当,并且与初步临床试验的良好结果一致。

相似文献

1
In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon.咯萘啶(本芴醇)对喀麦隆雅温得恶性疟原虫临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Sep;42(9):2347-51. doi: 10.1128/AAC.42.9.2347.
2
In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs.与标准抗疟药物相比,本芴醇对158株塞内加尔恶性疟原虫分离株的体外活性。
Antimicrob Agents Chemother. 1999 Feb;43(2):418-20. doi: 10.1128/AAC.43.2.418.
3
Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa.本芴醇及其对映体在来自东非的恶性疟原虫新鲜分离株中的活性。
Acta Trop. 1998 Jun 15;70(1):9-15. doi: 10.1016/s0001-706x(97)00141-1.
4
Desbutyl-benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand.去丁基-本芴醇,一种新型抗疟化合物:对来自泰国的恶性疟原虫新鲜分离株的体外活性
Antimicrob Agents Chemother. 2001 Jul;45(7):2106-9. doi: 10.1128/AAC.45.7.2106-2109.2001.
5
Synergism of benflumetol and artemether in Plasmodium falciparum.本芴醇与蒿甲醚对恶性疟原虫的协同作用。
Am J Trop Med Hyg. 1999 Sep;61(3):439-45. doi: 10.4269/ajtmh.1999.61.439.
6
In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos).老挝新发恶性疟原虫分离株的体外抗疟药物敏感性及pfcrt基因突变情况
Am J Trop Med Hyg. 2007 Feb;76(2):245-50.
7
In vitro sensitivity of Plasmodium falciparum to lumefantrine in north-western Thailand.泰国西北部恶性疟原虫对本芴醇的体外敏感性
Wien Klin Wochenschr. 2004;116 Suppl 4:41-6.
8
Interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum in vitro.双氢青蒿素与蒿甲醚单脱丁基衍生物在体外恶性疟原虫中的相互作用。
Wien Klin Wochenschr. 2008;120(19-20 Suppl 4):85-9. doi: 10.1007/s00508-008-1080-8.
9
In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon.双氢青蒿素对喀麦隆雅温得恶性疟原虫临床分离株的体外活性
Am J Trop Med Hyg. 1999 Aug;61(2):187-92. doi: 10.4269/ajtmh.1999.61.187.
10
Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand.氯氟菲醇与去丁基本芴醇对泰国间日疟原虫新鲜分离株的体外活性比较研究。
Wien Klin Wochenschr. 2004;116 Suppl 4:47-52.

引用本文的文献

1
antimalarial susceptibility profile of isolates in the BEI Resources repository.来自 BEI 资源库的 分离株的抗疟敏感性特征。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0118923. doi: 10.1128/aac.01189-23. Epub 2024 Sep 13.
2
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.青蒿琥酯-咯萘啶联合阿莫地喹与青蒿琥酯-咯萘啶单药治疗耐青蒿素、无并发症恶性疟原虫疟疾的疗效比较:一项开放标签、随机、多中心试验。
Lancet Infect Dis. 2022 Jun;22(6):867-878. doi: 10.1016/S1473-3099(21)00692-7. Epub 2022 Mar 8.
3
Chemoprophylaxis under sporozoites-lumefantrine (CPS-LMF) immunization induce protective immune responses against sporozoites infection in mice.子孢子下的氯氟菲醇化学预防(CPS-LMF)免疫可诱导小鼠针对子孢子感染产生保护性免疫反应。
3 Biotech. 2021 Nov;11(11):465. doi: 10.1007/s13205-021-03022-0. Epub 2021 Oct 19.
4
Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross.在恶性疟原虫交叉感染中 pfmdr1、pfcrt 和 pfk13 多态性与氯喹和青蒿琥酯敏感性的连锁证据。
Int J Parasitol Drugs Drug Resist. 2020 Dec;14:208-217. doi: 10.1016/j.ijpddr.2020.10.009. Epub 2020 Oct 27.
5
Determination of lumefantrine as an effective drug against infection - and study.测定青蒿琥酯对感染和疾病的有效药物作用。
Parasitology. 2021 Jan;148(1):122-128. doi: 10.1017/S0031182020002036. Epub 2020 Oct 22.
6
Recovery and stable persistence of chloroquine sensitivity in Plasmodium falciparum parasites after its discontinued use in Northern Uganda.在乌干达北部停止使用氯喹后,恶性疟原虫寄生虫对氯喹的敏感性得以恢复并持续存在。
Malar J. 2020 Feb 18;19(1):76. doi: 10.1186/s12936-020-03157-0.
7
Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether-lumefantrine treatment in Mali.在马里,口服蒿甲醚-本芴醇治疗后恶性疟原虫的体外药敏性降低。
Malar J. 2017 Feb 2;16(1):59. doi: 10.1186/s12936-017-1700-8.
8
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.使用基于模型的成本效益分析对比不同青蒿素联合疗法作为一线疟疾治疗方法的益处
Nat Commun. 2014 Nov 26;5:5606. doi: 10.1038/ncomms6606.
9
Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin.贝宁地区间日疟原虫多态性与基于青蒿素联合疗法的体外药物敏感性和临床疗效的关系。
Antimicrob Agents Chemother. 2014;58(1):1-10. doi: 10.1128/AAC.01790-12. Epub 2013 Oct 7.
10
A simple and precise method for quantitative analysis of lumefantrine by planar chromatography.一种通过平面色谱法对卤泛群进行定量分析的简单精确方法。
Pharm Methods. 2010 Oct;1(1):44-8. doi: 10.4103/2229-4708.72230.

本文引用的文献

1
Atovaquone - a novel broad-spectrum anti-infective drug.阿托伐醌——一种新型广谱抗感染药物。
Parasitol Today. 1993 Feb;9(2):66-8. doi: 10.1016/0169-4758(93)90040-m.
2
Pyronaridine: A new antimalarial drug.咯萘啶:一种新型抗疟药物。
Parasitol Today. 1991 Nov;7(11):310-3. doi: 10.1016/0169-4758(91)90267-r.
3
A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children.蒿甲醚/本芴醇(一种新型抗疟药)与乙胺嘧啶/磺胺多辛治疗非洲儿童无并发症恶性疟的随机对照试验。
Am J Trop Med Hyg. 1998 May;58(5):638-44. doi: 10.4269/ajtmh.1998.58.638.
4
Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria.新型速效有效口服抗疟药CGP 56697在中国进行的治疗恶性疟原虫疟疾的II期试验。
Southeast Asian J Trop Med Public Health. 1997 Sep;28(3):476-81.
5
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria.蒿甲醚-本芴醇与青蒿琥酯-甲氟喹治疗耐多药恶性疟的随机对照研究
Antimicrob Agents Chemother. 1998 Jan;42(1):135-9. doi: 10.1128/AAC.42.1.135.
6
Assessment of three in vitro tests and an in vivo test for chloroquine resistance in Plasmodium falciparum clinical isolates.对恶性疟原虫临床分离株氯喹抗性的三种体外试验和一种体内试验的评估。
J Clin Microbiol. 1998 Jan;36(1):243-7. doi: 10.1128/JCM.36.1.243-247.1998.
7
Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697.用一种新型抗疟药CGP 56697治疗非洲单纯性恶性疟原虫疟疾患儿。
J Infect Dis. 1997 Oct;176(4):1113-6. doi: 10.1086/516524.
8
Arteether: risks of two-week administration in Macaca mulatta.
Am J Trop Med Hyg. 1997 Apr;56(4):390-6. doi: 10.4269/ajtmh.1997.56.390.
9
Status of antimalarial drugs under development.正在研发的抗疟药物的现状。
Bull World Health Organ. 1995;73(5):565-71.
10
In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon.抗疟药对喀麦隆雅温得恶性疟原虫临床分离株的体外活性。
Am J Trop Med Hyg. 1996 Sep;55(3):254-8. doi: 10.4269/ajtmh.1996.55.254.